Back

Treatment with mTOR Inhibitors as primary immunosuppression after combined heart and kidney transplantation

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Before and after heart transplantation: new insights Heart Transplantation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hilmi Alnsasra

Soroka University Medical Center, Beer Sheva (Israel)

8 More presentations in this session

Presentation thumbnail
Stratification risk computation of primary graft gysfunction in heart transplant recipients on a smartphone application
Doctor S. Ait Tigrine (Paris, FR)
Abstract Slides Video
Presentation thumbnail
National trends of left ventricular assist device therapy in Germany
Doctor H. Seoudy (Kiel, DE)
Abstract Slides Video
Presentation thumbnail
Ventricular assist devices as bridge to heart transplantation: minimally invasive approach with axial pumps vs sternotomy approach with centrifugal pumps: short term results
Miss R. Ramos Martinez (Valladolid, ES)
Abstract Slides Video
Presentation thumbnail
Comparative analysis of multi-organ failure trajectories reflected by the MELD-3.0 following heart transplantation and heartmate 3 implantation
Mr J. Ptak (Wroclaw, PL)
Abstract Slides Video
Presentation thumbnail
Effect of disabling biventricular pacing in patients with left ventricular assist device and cardiac resynchronization therapy
Doctor M. Sawicka (Zabrze, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Before and after heart transplantation: new insights

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Use of PCSK9 inhibitors for hypercholesterolemia treatment after heart transplant in a multicenter cohort
thumbnail
Congress Presentation
Glucagon-like-peptide-1 receptor agonists in heart transplant recipients: is there any interaction with calcineurin inhibitors?
thumbnail
Congress Presentation
Lipoprotein (a) levels and cardiac allograft vasculopathy in heart transplant recipients: single centre experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources